JP2001515713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001515713A5 JP2001515713A5 JP2000510843A JP2000510843A JP2001515713A5 JP 2001515713 A5 JP2001515713 A5 JP 2001515713A5 JP 2000510843 A JP2000510843 A JP 2000510843A JP 2000510843 A JP2000510843 A JP 2000510843A JP 2001515713 A5 JP2001515713 A5 JP 2001515713A5
- Authority
- JP
- Japan
- Prior art keywords
- monocyte
- cells
- lesion
- derived
- site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 description 33
- 210000001616 monocyte Anatomy 0.000 description 20
- 230000003902 lesion Effects 0.000 description 15
- 239000000126 substance Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 208000014674 injury Diseases 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 210000001539 phagocyte Anatomy 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 239000005482 chemotactic factor Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002463 transducing effect Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/924,830 US20020068048A1 (en) | 1997-09-05 | 1997-09-05 | Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues |
| US08/924,830 | 1997-09-05 | ||
| PCT/EP1998/005707 WO1999013054A2 (en) | 1997-09-05 | 1998-08-31 | Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001515713A JP2001515713A (ja) | 2001-09-25 |
| JP2001515713A5 true JP2001515713A5 (https=) | 2006-01-05 |
Family
ID=25450795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000510843A Pending JP2001515713A (ja) | 1997-09-05 | 1998-08-31 | 散在性の若しくはアクセス困難な細胞又は組織を有するヒト病状の処置又は診断方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20020068048A1 (https=) |
| EP (1) | EP1009806A2 (https=) |
| JP (1) | JP2001515713A (https=) |
| AU (1) | AU752676B2 (https=) |
| CA (1) | CA2300387A1 (https=) |
| IL (1) | IL134393A0 (https=) |
| WO (1) | WO1999013054A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4544600A (en) * | 1999-04-06 | 2000-10-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Pharmaceutical compositions comprising circulating blood cells, preferably monocytes and uses thereof |
| DK1229940T3 (da) * | 1999-11-15 | 2014-08-18 | Piramal Healthcare Canada Ltd | Temperaturstyret og ph-afhængig selvgelerende, vandig biopolymeropløsning |
| HK1052645B (en) * | 2000-04-14 | 2008-03-20 | Universtiy Of Pittsburgh | Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof |
| WO2002040070A2 (en) * | 2000-11-15 | 2002-05-23 | Bio Syntech Canada Inc. | Method for restoring a damaged or degenerated intervertebral disc |
| MXPA05005051A (es) | 2002-11-12 | 2006-03-10 | Albert B Deisseroth | Vacuna de vector adenoviral. |
| CN103230415B (zh) * | 2003-04-25 | 2016-05-04 | 匹兹堡大学联邦制高等教育 | 用于促进和增强神经修复和再生的肌肉来源的细胞（mdc） |
| US8986736B2 (en) | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
| AU2004249172A1 (en) | 2003-06-24 | 2004-12-29 | Baxter International Inc. | Specific delivery of drugs to the brain |
| RU2006144851A (ru) | 2004-06-15 | 2008-06-20 | Бакстер Интернэшнл Инк. (Us) | Применение терапевтических средств ex-vivo в виде твердых микрочастиц |
| CA2672936A1 (en) * | 2006-11-30 | 2008-06-05 | Bio Syntech Canada Inc. | Method for in situ solidification of blood-polymer compositions for regenerative medicine and cartilage repair applications |
| RU2496482C2 (ru) | 2008-03-05 | 2013-10-27 | Бакстер Интернэшнл Инк. | Композиции и способы для доставки лекарственных средств |
| AU2009282619B2 (en) * | 2008-08-18 | 2015-08-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof |
| US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| GB201504251D0 (en) * | 2015-03-13 | 2015-04-29 | Virttu Biolog Ltd And University Of Sheffield The | Oncolytic herpes simplex virus infected cells |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2709309B1 (fr) * | 1993-08-25 | 1995-11-10 | Centre Nat Rech Scient | Compositions cellulaires, préparation et utilisations thérapeutiques. |
| FR2729570A1 (fr) * | 1995-01-24 | 1996-07-26 | Idm Immuno Designed Molecules | Procede de preparation de macrophages actives, trousses et compositions pour la mise en oeuvre de ce procede |
-
1997
- 1997-09-05 US US08/924,830 patent/US20020068048A1/en not_active Abandoned
-
1998
- 1998-08-31 IL IL13439398A patent/IL134393A0/xx unknown
- 1998-08-31 EP EP98947533A patent/EP1009806A2/en not_active Ceased
- 1998-08-31 CA CA002300387A patent/CA2300387A1/en not_active Abandoned
- 1998-08-31 JP JP2000510843A patent/JP2001515713A/ja active Pending
- 1998-08-31 WO PCT/EP1998/005707 patent/WO1999013054A2/en not_active Ceased
- 1998-08-31 AU AU94410/98A patent/AU752676B2/en not_active Ceased
-
2004
- 2004-01-30 US US10/766,929 patent/US20050048039A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102741405B (zh) | 提高基因表达的系统和保持有该系统的载体 | |
| JP2001515713A5 (https=) | ||
| EP0707071B1 (en) | Recombinant vectors derived from adenovirus for use in gene therapy | |
| CN102886052B (zh) | 长效药物制剂 | |
| US20160250290A1 (en) | Gene therapy for diabetic ischemic disease | |
| Bankiewicz et al. | Practical Aspects of the Development ofex Vivoandin VivoGene Therapy for Parkinson's Disease | |
| DE69432500T2 (de) | Rekombinante Foamy-Virus-Vektoren zur medizinischen und diagnostischen Verwendung und Verfahren zur Herstellung rekombinanter Foamy-Virus-Vektoren | |
| AU752676B2 (en) | Method for the treatment or diagnosis of human pathologies with disseminated or difficult to access cells or tissues | |
| JP2005504010A (ja) | 成長ホルモンおよびｆｏｘｍ１ｂを用いた肝臓疾患および肝臓損傷の処置方法 | |
| CN112567053A (zh) | 重组核酸构建体 | |
| US6613319B2 (en) | Long-term expression of erythropoietin and growth hormone by transforming muscle cells | |
| JP2001270840A (ja) | 免疫疾患の治療 | |
| JP3410738B2 (ja) | ミクログリアからなる医薬用キャリアー | |
| JP2024533396A5 (https=) | ||
| CN109748974B (zh) | 一种基因修饰的树突状细胞疫苗的制备及应用 | |
| EP4636093A1 (en) | Targeting mapk-erk pathway for enhancing nucleic acid delivery | |
| JP2003500336A (ja) | （自己）免疫疾患の治療におけるアポトーシス誘発剤の使用 | |
| DE19929104A1 (de) | Neue Vektorkomplexe und deren Verwendung für die Gentherapie | |
| CA2382464A1 (en) | High-affinity choline transporter | |
| JP2002524468A (ja) | プロサポシン受容体活性を刺激する方法 | |
| TWI309570B (https=) | ||
| KR19990072793A (ko) | Ｄｎａ서열의유전자수송을위한아데노바이러스전달벡터 | |
| JPH11513891A (ja) | 細胞系 | |
| JPWO2003004065A1 (ja) | Ｒｘｐ繰り返し配列を有するタンパク質を用いた生理的高分子の輸送方法 | |
| JP2005040005A (ja) | 組換えｄｎａ及びその用途 |